TAK — TAKEDA PHARMACEUTICAL CO LTD catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

7 verified catalyst event(s) for TAKEDA PHARMACEUTICAL CO LTD (ticker TAK). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-07-16 — A Study of TAK-360 in Adults With Idiopathic Hypersomnia · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-07-16 in 24d ESTIMATED	READOUT A Study of TAK-360 in Adults With Idiopathic Hypersomnia Phase 2 · Idiopathic Hypersomnia	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-08-20 in 2mo ESTIMATED	READOUT A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) Phase 2 · Narcolepsy Type 2	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-360	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-18 in 3mo ESTIMATED	READOUT A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the B Phase 2 · Crohn's Disease	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-279	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-09-30 in 3mo ESTIMATED	READOUT A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the B Phase 2 · Ulcerative Colitis	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-279	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-02 in 3mo ESTIMATED	READOUT A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-861	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-31 in 4mo ESTIMATED	READOUT A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Phase 1/2 · Carcinoma, Non-Small-Cell Lung	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-10-31 in 4mo ESTIMATED	READOUT TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788, Pemetrexed, Cisplatin, Carbopla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change